Monday, November 28, 2016
Synthorx Names Chief Business Officer
San Diego-based biotechnology developer Synthorx announced today that it has named Patrick J. Doyle as its Chief Business Officer. Doyle previously has served at Kinemed, Kareus Therapeutics, Syntaxin and Metabolex, and has more than 20 years of experience in the pharmaceutical R&D area, according to Synthorx. Synthorx is focused on developing novel protein therapeutics, and is venture backed by RA Capital Management, Avalon Ventures and Correlation Ventures. The company announced a funding round in July.